Table 2.
Patient background
| Insulin detemir group | Insulin aspart‐30 group | P‐value | |
|---|---|---|---|
| Sex (males/females) | 9/5 | 11/5 | 1.000* |
| Age (years) | 60.9 ± 6.8 | 59.0 ± 10.9 | 0.572** |
| BMI (kg/m2) | 24.4 ± 3.6 | 26.6 ± 4.0 | 0.140** |
| Urinary CPR (μg/day) | 69.0 ± 47.8 | 102.3 ± 63.0 | 0.118** |
| HbA1c at the initiation of insulin therapy (%) | 8.58 ± 0.43 | 8.88 ± 0.52 | 0.105** |
| Concomitant medication | |||
| Biguanides | 11 (79%) | 15 (94%) | 0.315* |
| Sulfonylureas | 13 (93%) | 16 (100%) | 0.467* |
| Thiazolidinediones | 7 (50%) | 9 (56%) | 1.000* |
Data are expressed as mean ± standard deviation. *Fisher's exact test. **The t‐test. BMI, body mass index; CPR, C‐peptide immunoreactivity; HbA1c, glycated hemoglobin.